You can buy or sell Syneos Health and other stocks, options, ETFs, and crypto commission-free!
Syneos Health, Inc. engages in the provision of product development and commercial solutions. It operates though the Clinical Solutions and Commercial Solutions segments. Read More The Clinical Solutions segment offers clinical development services spanning Phase I to Phase IV, including global studies, as well as unbundled service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. The company was founded on August 13, 2010 and is headquartered in Raleigh, NC.
Raleigh, North Carolina
52 Week High
52 Week Low
Syneos Health Inc. Cl A
Breaking Syneos Health Inc. revealed Wednesday afternoon that the Securities and Exchange Commission is investigating its accounting procedures. Trading was paused before the news was announced, and shares fell 23% in after-hours action after trading restarted. In a news release, the biopharmaceutical-services company said that it was delaying the release of its earnings results to allow additional time to review the company's internal controls over financial reporting after receiving notification of an in...
Associated PressMar 19
Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Syneos Health, Inc.
This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation. This content is a press release from our partner Business Wire. The AP newsroom and editorial departments were not involved in its creation. LOS ANGELES--(BUSINESS WIRE)--Mar 19, 2019--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the April 30, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Syne...
$0.82 per share
$0.95 per share